AcelRx Pharmaceuticals Inc. [NASDAQ: ACRX] loss -11.12% on the last trading session, reaching $0.26 price per share at the time. The company report on May 20, 2022 that AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (“AcelRx”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.
H.C. Wainwright Global Investment ConferenceFormat: Live presentation and 1×1 MeetingsDate: Tuesday, May 24th, 2022Time: 3:30 PM EDT]Webcast Link: https://journey.ct.events/view/c7c39615-b777-44ea-aa7a-3c782e6247ac.
AcelRx Pharmaceuticals Inc. represents 145.62 million in outstanding shares, while the company has a total market value of $43.79 million with the latest information. ACRX stock price has been found in the range of $0.251 to $0.30.
If compared to the average trading volume of 2.06M shares, ACRX reached a trading volume of 2781773 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AcelRx Pharmaceuticals Inc. [ACRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRX shares is $4.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for AcelRx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $7 to $2. The new note on the price target was released on November 11, 2019, representing the official price target for AcelRx Pharmaceuticals Inc. stock.
The Average True Range (ATR) for AcelRx Pharmaceuticals Inc. is set at 0.04, with the Price to Sales ratio for ACRX stock in the period of the last 12 months amounting to 16.22.
Trading performance analysis for ACRX stock
AcelRx Pharmaceuticals Inc. [ACRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.00. With this latest performance, ACRX shares gained by 22.14% in over the last four-week period, additionally sinking by -52.82% over the last 6 months – not to mention a drop of -78.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRX stock in for the last two-week period is set at 51.74, with the RSI for the last a single of trading hit 49.83, and the three-weeks RSI is set at 51.62 for AcelRx Pharmaceuticals Inc. [ACRX]. The present Moving Average for the last 50 days of trading for this stock 0.2297, while it was recorded at 0.2985 for the last single week of trading, and 0.4787 for the last 200 days.
AcelRx Pharmaceuticals Inc. [ACRX]: A deeper dive into fundamental analysis
AcelRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
An analysis of insider ownership at AcelRx Pharmaceuticals Inc. [ACRX]
There are presently around $6 million, or 13.70% of ACRX stock, in the hands of institutional investors. The top three institutional holders of ACRX stocks are: ROCK SPRINGS CAPITAL MANAGEMENT LP with ownership of 6,329,202, which is approximately 0.052% of the company’s market cap and around 1.70% of the total institutional ownership; D. E. SHAW & CO., INC., holding 3,808,993 shares of the stock with an approximate value of $1.1 million in ACRX stocks shares; and VANGUARD GROUP INC, currently with $1.0 million in ACRX stock with ownership of nearly -31.913% of the company’s market capitalization.
Positions in AcelRx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 15 institutional holders increased their position in AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] by around 553,436 shares. Additionally, 26 investors decreased positions by around 10,766,381 shares, while 23 investors held positions by with 8,534,512 shares. The mentioned changes placed institutional holdings at 19,854,329 shares, according to the latest SEC report filing. ACRX stock had 6 new institutional investments in for a total of 191,940 shares, while 11 institutional investors sold positions of 8,615,140 shares during the same period.